Among the genes upregulated in hypoxia in both DMSO- and onametostat-treated cells, the atypical chemokine receptor 3 (ACKR3) has been explored in the context of cardiovascular diseases and inflammation57, the nerve growth factor (NGF) in the context of angiogenesis in non-small cell lung cancer58, and the 4-hydroxyphenylpyruvate dioxygenase (HPD) in the context of metabolic reprogramming in lung cancer59. This evidence concerns the gene ACKR3 and cardiovascular disorder.